Literature DB >> 2252808

Phenytoin affects osteocalcin secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture.

A T Vernillo1, B R Rifkin, P V Hauschka.   

Abstract

5,5-diphenylhydantoin (Phenytoin, PHT), a widely used anticonvulsant, is also a vitamin K antagonist and disrupts bone metabolism, leading to osteomalacia. The vitamin K-dependently synthesized protein, osteocalcin, has been implicated as a key regulatory protein in bone resorption. The purpose of the present study was to determine whether PHT had an effect on osteocalcin secretion. Cells were grown to confluence in Ham's F-12 nutrient mixture, and treated with 1,25 (OH)2 vitamin D3 (2.6 microM to 2.6 pM) or PHT (5-100 micrograms/mL) for either 24 or 48 h of pretreatment. The media were then discarded, replaced with fresh media and test reagents, and quantitated for osteocalcin by radioimmunoassay at 0, 4, and 8 h secretion time points. Results were statistically analyzed by the Student's two-tailed t test. Controls showed a nearly linear secretion rate of osteocalcin, reaching 8-9 ng/10(6) cells by 8 h. Vitamin D3 (2.6 nM) maximally stimulated secretion nearly two-fold after 24 or 48 h of pretreatment in comparison to controls. PHT alone (25-100 micrograms/mL) exerted an inhibitory effect, which appeared dose-dependent and was most evident at 4 and 8 h. PHT (50 micrograms/mL) had a significant effect, in the presence of a range of vitamin D3 concentrations (2.6 microM to 2.6 pM), after 48 h of pretreatment. A maximal PHT dose of 100 micrograms/mL had no effect on either the viability or the numbers of cultured cells. These data indicate that PHT affects osteocalcin secretion from osteoblastic rat osteosarcoma (ROS 17/2.8) cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2252808     DOI: 10.1016/8756-3282(90)90085-d

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  8 in total

1.  The Association Between Antiepileptic Drugs and Bone Disease.

Authors:  Alison M. Pack
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

2.  Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy.

Authors:  Alison M Pack; Martha J Morrell; Robert Marcus; Leah Holloway; Edith Flaster; Silvia Doñe; Alison Randall; Cairn Seale; Elizabeth Shane
Journal:  Ann Neurol       Date:  2005-02       Impact factor: 10.422

Review 3.  Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.

Authors:  A M Pack; M J Morrell
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy.

Authors:  Sina Nettekoven; Alexander Ströhle; Birgit Trunz; Maike Wolters; Susanne Hoffmann; Rüdiger Horn; Martin Steinert; Georg Brabant; Ralf Lichtinghagen; Hans-Jürgen Welkoborsky; Ingrid Tuxhorn; Andreas Hahn
Journal:  Eur J Pediatr       Date:  2008-02-13       Impact factor: 3.183

Review 5.  Bone disease in epilepsy.

Authors:  Alison M Pack
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

6.  May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism?

Authors:  O Babacan; A Karaoglu; S Vurucu; E Yesilkaya; O Yesilyurt; T Cayci; M Gulgun; B Unay; R Akın; O Ozcan
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

7.  Association of 25-Hydroxyvitamin D Deficiency in Pediatric Epileptic Patients.

Authors:  Jaydip Ray Chaudhuri; Kandadai Rukmini Mridula; Chakrala Rathnakishore; Banda Balaraju; Vcs Srinivasarao Bandaru
Journal:  Iran J Child Neurol       Date:  2017

8.  Bone health in pediatric patients with neurological disorders.

Authors:  Ara Ko; Juhyun Kong; Furkat Samadov; Akmal Mukhamedov; Young Mi Kim; Yun-Jin Lee; Sang Ook Nam
Journal:  Ann Pediatr Endocrinol Metab       Date:  2020-03-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.